[go: up one dir, main page]

AR022636A1 - Derivados de la 16-halo-epotilona, los procedimientos para prepararlos y el empleo farmaceutico de los mismos - Google Patents

Derivados de la 16-halo-epotilona, los procedimientos para prepararlos y el empleo farmaceutico de los mismos

Info

Publication number
AR022636A1
AR022636A1 ARP000100714A ARP000100714A AR022636A1 AR 022636 A1 AR022636 A1 AR 022636A1 AR P000100714 A ARP000100714 A AR P000100714A AR P000100714 A ARP000100714 A AR P000100714A AR 022636 A1 AR022636 A1 AR 022636A1
Authority
AR
Argentina
Prior art keywords
derivatives
epotilone
employment
halo
pharmaceutical
Prior art date
Application number
ARP000100714A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19908765A external-priority patent/DE19908765A1/de
Priority claimed from DE19954230A external-priority patent/DE19954230A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR022636A1 publication Critical patent/AR022636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Nuevos derivados de la epotilona de formula general (1) en donde R8 representa un átomo de halogeno, en particular un átomo de fluor o cloro, y los demássustituyentes tienen el significado indicado en la memoria descriptiva. Los nuevos compuestosson apropiados para preparar medicamentos.
ARP000100714A 1999-02-18 2000-02-21 Derivados de la 16-halo-epotilona, los procedimientos para prepararlos y el empleo farmaceutico de los mismos AR022636A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19908765A DE19908765A1 (de) 1999-02-18 1999-02-18 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A DE19954230A1 (de) 1999-11-04 1999-11-04 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Publications (1)

Publication Number Publication Date
AR022636A1 true AR022636A1 (es) 2002-09-04

Family

ID=26052117

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100714A AR022636A1 (es) 1999-02-18 2000-02-21 Derivados de la 16-halo-epotilona, los procedimientos para prepararlos y el empleo farmaceutico de los mismos

Country Status (27)

Country Link
US (3) US6610736B1 (es)
EP (1) EP1150980B1 (es)
JP (1) JP2002537301A (es)
KR (1) KR100718616B1 (es)
CN (1) CN1209360C (es)
AR (1) AR022636A1 (es)
AT (1) ATE370946T1 (es)
AU (1) AU3156700A (es)
BG (1) BG105802A (es)
BR (1) BR0008331A (es)
CA (1) CA2361278A1 (es)
CZ (1) CZ20012951A3 (es)
DE (1) DE50014587D1 (es)
EA (1) EA009206B1 (es)
EE (1) EE200100431A (es)
ES (1) ES2291194T3 (es)
HR (1) HRP20010677A2 (es)
HU (1) HUP0105478A3 (es)
IL (1) IL144519A0 (es)
MX (1) MXPA01008328A (es)
NO (1) NO20014013L (es)
NZ (1) NZ513268A (es)
PL (1) PL349863A1 (es)
SK (1) SK11852001A3 (es)
TW (1) TWI285645B (es)
WO (1) WO2000049021A2 (es)
YU (1) YU59001A (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1196698C (zh) 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
WO2002062338A1 (en) 2001-01-25 2002-08-15 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
KR20040025895A (ko) 2001-02-20 2004-03-26 브리스톨-마이어스스퀴브컴파니 에포틸론 유도체를 사용하는 치료불응성 종양의 치료
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
BRPI0207961B8 (pt) 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EP1392664A4 (en) 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2003077903A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
RU2462463C2 (ru) * 2002-08-23 2012-09-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2281692T3 (es) * 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
HRP20050278A2 (en) 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US20070014978A1 (en) * 2005-07-18 2007-01-18 Anthony Poloso Method of flame blocking and articles made therefrom
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc BINDING COMPOUNDS TO THE IAP BIR DOMAIN
EP2065054A1 (en) * 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
GB202309910D0 (en) * 2023-06-29 2023-08-16 Implexion Pharma Ab Therpay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353732A3 (de) * 1988-08-05 1991-11-06 Ciba-Geigy Ag Neue Fluorolefine, Verfahren zu deren Herstellung und deren Verwendung
JP2685521B2 (ja) 1988-08-05 1997-12-03 株式会社日立製作所 車両用換気装置
CN1053428A (zh) * 1989-12-27 1991-07-31 孟山都公司 取代吡啶化合物
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
AU5036999A (en) * 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
WO2000049021A3 (de) 2000-12-28
BG105802A (bg) 2002-03-29
KR20010102215A (ko) 2001-11-15
KR100718616B1 (ko) 2007-05-16
YU59001A (sh) 2005-07-19
NO20014013D0 (no) 2001-08-17
AU3156700A (en) 2000-09-04
IL144519A0 (en) 2002-05-23
HUP0105478A3 (en) 2002-08-28
MXPA01008328A (es) 2002-06-04
CZ20012951A3 (cs) 2001-11-14
EE200100431A (et) 2002-12-16
US6930102B2 (en) 2005-08-16
BR0008331A (pt) 2002-01-29
EP1150980A2 (de) 2001-11-07
HK1044945A1 (en) 2002-11-08
US20050187270A1 (en) 2005-08-25
EA200100826A1 (ru) 2002-02-28
WO2000049021A2 (de) 2000-08-24
EP1150980B1 (de) 2007-08-22
JP2002537301A (ja) 2002-11-05
CN1341115A (zh) 2002-03-20
US6610736B1 (en) 2003-08-26
CN1209360C (zh) 2005-07-06
US20040014978A1 (en) 2004-01-22
HUP0105478A2 (en) 2002-06-29
SK11852001A3 (sk) 2002-04-04
HRP20010677A2 (en) 2005-06-30
DE50014587D1 (de) 2007-10-04
PL349863A1 (en) 2002-09-23
ES2291194T3 (es) 2008-03-01
CA2361278A1 (en) 2000-08-24
EA009206B1 (ru) 2007-12-28
NO20014013L (no) 2001-10-18
ATE370946T1 (de) 2007-09-15
TWI285645B (en) 2007-08-21
NZ513268A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
AR022636A1 (es) Derivados de la 16-halo-epotilona, los procedimientos para prepararlos y el empleo farmaceutico de los mismos
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ATE450533T1 (de) Carboxamidderivate
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
NO20013469D0 (no) Fremgangsmåter for glukagonsuppresjon
PA8545301A1 (es) Nuevos derivados de quinolina
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
DK1212312T3 (da) Hidtil ukendte derivater af flavoner, xanthoner og coumariner
SE0302192D0 (sv) Novel compounds
DK1578741T3 (da) Aromatiske forbindelser som anti-inflammatoriske, immunmodulatoriske og anti-proliferative midler
EE03771B1 (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
DK1455761T3 (da) Farmaceutiske præparater til oral administration af heparin eller derivater deraf
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
UY28537A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
DE69813263T2 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
TW200510370A (en) Urea derivatives
DK0478416T3 (da) Anvendelse af triazin- og pyrimidinderivater til opnåelse af lægemidler, som omvender modstandsdygtigheden over for cancermidler og malarismidler
PA8576701A1 (es) Derivados de quinazolina

Legal Events

Date Code Title Description
FB Suspension of granting procedure